{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-089443","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2026-08-03T11:07:36+00:00","discovered_at":"2026-08-03T11:10:00.393513+00:00","generated_at":"2026-08-03T11:10:08.147572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix Q2 2026 net loss $78.8M; AXPAXLI NDA on track for Q4 2026","bullets":["Net loss of $78.8M ($0.35 per share) for Q2 2026, vs. $67.8M loss in Q2 2025.","Cash balance $598.6M as of June 30, 2026; expected runway into 2028.","AXPAXLI NDA submission for wet AMD planned for Q4 2026 after FDA Type C meeting alignment.","Post-hoc SOL-1 analysis shows up to 72% reduction in treatment burden vs. aflibercept (2 mg) over 60 weeks.","DEXTENZA revenue flat at $13.5M; R&D expenses $54.1M, up from $51.1M in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-089443","json":"https://secwatch.observer/filing/0001104659-26-089443.json","markdown":"https://secwatch.observer/filing/0001104659-26-089443.md","text":"https://secwatch.observer/filing/0001104659-26-089443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/0001104659-26-089443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:10:08.147572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}